Can an elderly female patient with a resolved deep‑vein thrombosis, who has been on apixaban (Eliquis) 5 mg twice daily for eight months and is also taking clopidogrel (Plavix) for a prior coronary stent, safely discontinue apixaban?

Can Apixaban Be Safely Discontinued in This Patient?

No, apixaban should not be discontinued at this time—she should continue clopidogrel alone for her coronary stents, as the DVT has been adequately treated for 8 months and recent ultrasound is negative. 1

Key Clinical Context

This patient has two distinct indications for antithrombotic therapy that must be managed separately:

• Resolved provoked DVT (8 months of treatment completed, negative repeat ultrasound)
• Prior coronary stent placement requiring antiplatelet therapy with clopidogrel

Duration of Anticoagulation for DVT

Standard Treatment Duration

• For provoked DVT, the recommended duration is 3 months of anticoagulation, after which therapy should be stopped rather than continuing extended therapy. 2, 3
• At 8 months, this patient has exceeded the recommended treatment duration by 5 months 2
• The negative repeat ultrasound confirms DVT resolution 2

No Indication for Extended Therapy

• Extended anticoagulation beyond 3 months is indicated for unprovoked DVT or when enduring risk factors persist 3
• The question does not indicate this was unprovoked DVT or that enduring risk factors are present 3
• After completing the initial 3-month treatment period for provoked DVT, anticoagulation should be discontinued 2, 3

Managing Dual Antithrombotic Needs

Timing Since Stent Placement

The critical question is: How long has it been since her stent placement?

• If >12 months post-PCI: Stop apixaban and continue clopidogrel alone 1
• If 6-12 months post-PCI: Continue single antiplatelet therapy (clopidogrel) until 12 months post-PCI, then reassess 1
• If <6 months post-PCI: This would have required triple therapy initially, but at 8 months post-DVT diagnosis, she is likely beyond this window 1

Recommended Approach

The appropriate management is to discontinue apixaban and continue clopidogrel monotherapy for her coronary stents. 1

• For patients on antiplatelet therapy for stable ischemic heart disease with prior PCI who develop VTE requiring anticoagulation, once >12 months post-PCI, an oral anticoagulant alone can be used long-term—but in this case, the VTE indication has been completed 1
• After completing VTE treatment, she should return to single antiplatelet therapy (clopidogrel) for her stents 1

Critical Safety Considerations

Bleeding Risk with Dual Therapy

• Continuing both apixaban and clopidogrel unnecessarily increases major bleeding risk without added benefit once the DVT treatment course is complete 1
• The combination of anticoagulation and antiplatelet therapy substantially increases bleeding risk 2

Premature Discontinuation Warning

• The FDA label warns that premature discontinuation of apixaban increases thrombotic risk 4
• However, discontinuation after completing an appropriate course of therapy (3 months for provoked DVT) is not considered "premature" 4
• At 8 months, she has completed more than the recommended duration 2, 3

Common Pitfalls to Avoid

1. Do not confuse the 6-month timepoint for dose reduction with the treatment endpoint. The reduced-dose apixaban 2.5 mg twice daily is only for extended secondary prevention in patients with unprovoked VTE or ongoing risk factors—not for provoked DVT 2, 3

2. Do not continue anticoagulation indefinitely for provoked DVT. This increases bleeding risk without reducing recurrence risk in patients whose provoking factor has resolved 2, 3

3. Do not stop clopidogrel. She still requires antiplatelet therapy for her coronary stents; only the anticoagulation for DVT should be discontinued 1

4. Assess the exact timing of stent placement. If she is within 12 months of PCI, continue clopidogrel until that milestone; if beyond 12 months, the duration of antiplatelet therapy should be based on her overall cardiovascular risk 1

Implementation Plan

1. Discontinue apixaban immediately (treatment course complete at 8 months for provoked DVT) 2, 3
2. Continue clopidogrel for coronary stent protection 1
3. Reassess antiplatelet therapy duration based on time since stent placement and overall cardiovascular risk 1
4. Counsel the patient that stopping apixaban is appropriate because her DVT has been adequately treated and resolved 2, 3